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► Sustainable medication prescribing treats patient and environment as integral whole.
► Medication dose can often be reduced while still achieving therapeutic targets.
► Reduced dose translates into lower environmental loadings of excreted drug residues.
► Reduced dose can help prevent adverse side effects, drug diversion, and poisonings.
► Reduced dose can lessen cost of health care and reduce need for waste treatment.Abbreviations: APIs, active pharmaceutical ingredie
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Environmental impactThe prescribed use of pharmaceuticals can result in unintended, unwelcomed, and potentially adverse conse-
quences for the environment and for those not initially targeted for treatment. Medication usage frequently re-
sults in the collateral introduction to the environment (via excretion and bathing) of active pharmaceutical
ingredients (APIs), bioactive metabolites, and reversible conjugates. Imprudent prescribing and non-compliant
patient behavior drive the accumulation of unusedmedications, which posemajor public health risks fromdiver-
sion as well as risks for the environment from unsound disposal, such as ﬂushing to sewers. The prescriber has
the unique wherewithal to reduce each of these risks bymodifying various aspects of the practice of prescribing.
By incorporating consideration of the potential for adverse environmental impacts into the practice of prescrib-
ing, patient care also could possibly be improved and public health better protected.
Although excretion of an API is governed by its characteristic pharmacokinetics, this variable can be some-
what controlled by the prescriber in selecting APIs possessing environment-friendly excretion proﬁles and
in selecting the lowest effective dose. This paper presents the ﬁrst critical examination of the multi-faceted
role of drug dose in reducing the ambient levels of APIs in the environment and in reducing the incidence
of drug wastage, which ultimately necessitates disposal of leftovers. Historically, drug dose has been actively
excluded from consideration in risk mitigation strategies for reducing ambient API levels in the environment.
Personalized adjustment of drug dose also holds the potential for enhancing therapeutic outcomes while simul-
taneously reducing the incidence of adverse drug events and in lowering patient healthcare costs. Optimizing
drug dose is a major factor in improving the sustainability of health care. The prescriber needs to be cognizant
that the “patient” encompasses the environment and other “bystanders,” and that prescribed treatments can
have unanticipated, collateral impacts that reach far beyond the healthcare setting.
Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Pharmaceuticals play a major and growing role in therapeutic in-
terventions practiced in Western allopathic medicine. Assuming thatnts; FDA, U.S. Food and Drug
eﬁned daily dose; PBT, persis-
uptake inhibitor.
+1 702 798 2142.
Daughton),
BY-NC-ND license.the most efﬁcacious drug is selected by the prescriber, the major
variable in achieving successful outcomes is dose. It is a well accepted
medical practice to alter dose based on desired clinical response coupled
with avoidance of adverse reactions. Less well known is that dose also
plays a major role in a wide spectrum of collateral but largely hidden
effects extending far beyond the immediate patient. Dose determines
the quantities of active pharmaceutical ingredients (APIs) that are con-
tinually released to the environment via excretion, bathing (as a result
of topical administration and excretion via sweat), and disposal of
unwanted leftovers. Despite its critical role and the ramiﬁcations
that derive from strictly adhering to “approved” usage, dose receives
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optimized.
Drug dose has long been actively excluded from risk mitigation
strategies for achieving reductions in ambient API levels in the envi-
ronment. Drug dose has long been mistakenly assumed to be a pa-
rameter not amenable to control. By reducing dose (to levels below
on-label guidelines), therapeutic goals can often still be met — or
sometimes even exceeded (by minimizing adverse effects and there-
by facilitating compliant patient behavior)— and patient expense can
be reduced.
Dose is the major focus of this discourse. Presented is the ﬁrst crit-
ical examination of the multi-faceted role that optimal drug dose
could play in reducing the ambient levels of APIs in the environment
and in reducing the incidence of drug wastage, which ultimately neces-
sitates disposal of leftovers. Provided is theﬁrst framework for how a ra-
tional approach to dose selection during prescribing/dispensing could
greatly assist in reducing the multiple and interconnected adverse im-
pacts of medication usage on human health, cost of medical care, public
safety, and the environment.
Strategies for addressing environmental problems resulting from
the practice of health care have historically failed to incorporate sustain-
able solutions because they involve the communication and collaboration
of twodisparate professions that rarely interact—namely health care and
environmental science. A major objective of this paper is to bridge the
disconnect between medicine and environmental science — to foster
communication and collaboration between medical care professionals
and environmental scientists. It is important for both disciplines to un-
derstand the unique challenges faced by both — particularly how the
practice of medication prescribing could be improved by incorporating
some of the principles of environmental sustainability.2. Background and rationale: bystander and environmental impacts
of prescribing
Imprudent or inappropriate prescribing— including over-prescribing,
mis-prescribing, and “marginal medicine” (Hoffman and Pearson,
2009) — includes unsupported off-label (“unapproved”) indications,
higher-than-necessary dose strengths (which can also overlap with
the on-label dose range), and larger-than-needed dose quantities
or longer-than-needed durations. All of these can contribute to the
accumulation by the patient of unused medications (as a result of
non-compliant or non-adherent patient behavior — partly driven by
adverse drug reactions or patient confusion caused by polypharmacy).
The patient is then faced with the frustration of wasted investment
and burdened by the added responsibility, hazards, and liabilities asso-
ciated with either storing or disposing of the wasted medications — all
made worse in the U.S. by the absence of a nationwide approach for
safe, efﬁcient, and timely disposal (Daughton, 2010a).
Unused, accumulated medications promote drug diversion to
others (with attendant abuse, misuse, and other risks posed by
self-medication). Their unsecured storage by consumers facilitates
unintended poisonings for others (a leading cause of overall poison-
ings among children, including mortality). Their imprudent disposal
can amplify the introduction of APIs to the environment (with atten-
dant societal costs imposed by the need for mitigation or remedia-
tion). They often represent signiﬁcant wasted healthcare resources.
And they can serve as a stark measure of failure to achieve treatment
goals (Daughton and Ruhoy, 2011). Some of these concerns are be-
coming better recognized by the healthcare community (e.g., see:
Donini-Lenhoff, 2012). The far-reaching effects of imprudent pre-
scribing are discussed elsewhere in the literature and are beyond
the scope of this paper. Supporting evidence for prudent prescribing
can usually be found in authoritative, peer-reviewed sources and clin-
ical trials, often made more accessible in updated compilations such
as drug bulletins (Olsson and Pal, 2006).Large and chemically diverse arrays of APIs compose the armamen-
tarium of medications and diagnostic agents available to the large spec-
trum of healthcare professions. The expanding universe of biochemical
targets (Imming et al., 2006) will continue to drive the development of
numerous, new small-molecule drug entities (Reymond and Awale,
2012). Small-molecule pharmaceuticals are ubiquitous throughout
society (Ruhoy and Daughton, 2008), as shown by a complex network
of sources and ultimate fates of APIs in the environment (Daughton,
2008; see Fig. 1 therein, illustration also available: http://www.epa.
gov/nerlesd1/bios/daughton/drug-lifecycle.pdf). This will exacerbate
the growing concerns surrounding environmental stewardship and
public health and safety — the imperative to prevent drug diversion,
abuse, overuse/misuse, and unintended poisonings (Daughton, 2010a).
Environmental stewardship for drugs partly involves the need to reduce
the incidence of APIs as ubiquitous contaminants of water resources,
aquatic wildlife, the terrestrial environment, and food sources. An
additional environmental burden of APIs (especially antibiotics and
hormones) emanates from their frequent use in agriculture (especially
conﬁned animal feeding operations and aquaculture) (e.g., Bartelt-Hunt
et al., 2011). Absent, however, is a cohesive strategy for ensuring that
the processes feeding these pathways are optimized to reduce the
entry of APIs to our immediate and ambient environments— strategies
focused onwaste reduction and pollution prevention. Such a strategy is
required to create a sustainable, uniﬁed system for the optimally effec-
tive use of pharmaceuticals.
We propose that the fundamental cause for this disconnect and in-
efﬁciencies is the failure to recognize that the practices governing the
use of pharmaceuticals in health care could be re-designed to lessen
all of the downstream burdens. These strategies would yield reductions
in: (i) the release to sewers of administeredAPIs—primarily via excretion
and secondarily via bathing and (ii) the generation of leftover medica-
tions. Two strategies in particular have long been discounted as infeasible
or imprudent: (1) prescribing lower doses and (2) evidence-based se-
lection of APIs guided in part by their excretion proﬁles (prescribing
those APIs displaying minimal excretion of the parent drug, bioactive
products, or reversible metabolic conjugates) (Daughton and Ruhoy,
2011). This discussion focuses on the ﬁrst strategy; the second strategy
requires considerablymore supporting data and effort to present and is
the possible subject of a future paper.
Impudent use of medication undoubtedly plays a signiﬁcant role
in three of the six primary categories of waste in the U.S. healthcare
system identiﬁed by a recent administrator of the Centers for Medicare
and Medicaid Services, namely: (1) failures of care delivery, (2) failures
of care coordination, and (3) overtreatment (Berwick and Hackbarth,
2012). These three categories compose a portion of the minimum esti-
mated 20% waste of healthcare resource expenditures in the U.S. This is
corroborated by a 2011 survey of U.S. primary care physicians, where
42% of respondents felt that the patients in their own practices received
toomuch care (Sirovich andWoloshin, 2011); undoubtedly, an unknown
portion of this directly involved over-treatment withmedications. A por-
tion of over-treatment may well derive from unfounded patient de-
mands, partly driven by misinformed beliefs of patients regarding drug
effectiveness and safety. For example, a recent U.S. survey of the public's
knowledge of the drug approval process revealed that 39% believed that
the U.S. Food and Drug Administration (FDA) approves only “extremely
effective drugs” and 25%believed that the FDA approves only “drugs lack-
ing serious side effects” (Schwartz and Woloshin, 2011).
Despite its association with off-label use, prudent low-dose pre-
scribing could have major positive outcomes by: (i) reducing the
loadings of APIs in the environment, (ii) protecting public health by
reducing drug diversion (and the profound problems with attendant
abuse of certain drugs andmisuse of others) and unintended poisonings
by drugs (especially infants, toddlers, and children), (iii) improving
public trust—by reducing hidden andunwelcomed exposure of humans
to trace levels of numerous APIs via potable water and contaminated
foods, and (iv) improving health care —with more efﬁcient attainment
Fig. 1. One-size-ﬁts-all drug dosing: risks to health and the environment, and increased health care costs.
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reduced patient costs. Although such an impressive list of collateral
outcomes and goals might seem speculative, outlined here are the
principles underlying a framework for their achievement.
A ﬁnal note is important for perspective regarding the potential
signiﬁcance of APIs as contaminants in the ambient environment.
Even though the levels of most APIs identiﬁed in the environment
(especially the aquatic environment) are extremely low (many orders
of magnitude lower than human plasma levels during therapeutic use),
ecotoxicological research continually pushes the lowest observed ef-
fect levels (LOELs) even lower. One example of exquisite sensitivityis a study of the effects on freshwater snails by the antidepressants
venlafaxine and citalopram. Exposure levels in the sub-nanogram
per liter range or 10−12M [up to 4 orders of magnitude below those
known to occur in treated sewage efﬂuent (e.g., see: Lajeunesse et al.,
2012)] induced persistent foot detachment from the native substrate
(Fong and Hoy, 2012). Such an alteration to behavior could prove ad-
verse by affecting predator avoidance; many other examples of aquatic
effects from exposures to low, ambient levels of APIs have been
reported (see reviews: Corcoran et al., 2010; Santos et al., 2010). For
humans, a parallel concern is those drugs with single-dose lethality to
children. These drugs can be lethal to children in whole-body doses of
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be up to several orders of magnitude more potent than the most toxic
pesticides currently available for consumer use (Daughton, 2010a).
3. Objectives of sustainable prescribing — beyond therapeutic
outcomes and minimizing adverse effects
When prescribing a medication, it should provide the desired thera-
peutic outcome while minimizing adverse side effects and cost to the
patient. The side effects, dosage, frequency and ease of administration,
and other factors involved with the prescribed regimen must also not
defeat compliance or discourage adherence by the patient. These goals
can prove challenging to optimize because of competing trade-offs.
While this traditional decision process for prescribing might be
complex, the complexity is largely lost in the day-to-day prescribing
practices of healthcare providers because selection of medication
type and dose is often based on an individual prescriber's experience
with the use of particular medications in the context of a particular dis-
ease or somatic complaint. Consideration of large-scale studies, pharma-
cokinetics, other effective practices, and environmental stewardship are
generally beyond the abilities of the time-restrained physicians.
For a truly sustainable system of healthcare, however, additional fac-
tors must be considered for a holistic, comprehensive, and prudent pre-
scribing process (see Table 1). Of course, there are many additional ﬁne
points associated with each of these factors that serve to complicate gen-
eralizations. For example, although certainAPIs are refractory to chemical
alteration by engineered treatment systems used for upgrading or san-
itizing sewage or drinking water [e.g., diclofenac, carbamazepine, and
cetirizine (deGraaff et al., 2011)] or by awide array of natural processes
in the environment, other APIs are readily degraded and would pose
lower potential for environmental impacts.
3.1. Prescribing to patients includes unintended prescribing to “bystanders”
Every prescription holds the potential for a downstream cascade of
adverse impacts on the patient as well as others and the environment.Table 1
Objectives of sustainable prescribing beyond therapeutic objectives and minimizing
adverse effects.
Sustainable, environmentally sound prescribing should attempt to minimize
Continual entry of APIs into sewers (traces can later contaminate drinking waters
and food supplies)
• Excretion of unmetabolized APIs via urine, feces, and sweat
• Excretion of bioactive metabolites
• Excretion of reversible metabolic conjugates (whose hydrolysis can liberate the API)
• Release of APIs via bathing (after topical application or excretion via sweating)
• Disposal of unused drugs and used delivery devices (such as transdermal patches)
Generation of leftover, unused medications
• Unnecessarily increases consumer expense
• Excessive prescribed quantities or complex regimens (exacerbated by polypharmacy)
can promote non-compliant patient behavior
• May facilitate addiction, abuse, or misuse
• Facilitates storage/stockpiling, which may encourage diversion for second-hand use,
including recreational use (such as pharm parties), drug sharing, and imprudent
self-medication by others
• Imposes need for disposal of substantial quantities; disposal to sewers or trash can im-
pose environmental ormitigation costs; prudent disposal via consumer take-back pro-
grams imposes societal infrastructure costs and increases environmental footprint
(e.g., emissions from transportation and incineration)
Potential for accidental and unintended poisonings
• Risk exacerbated by practices that promote the generation of leftover medications
(which may lead to unsecured storage or imprudent disposal)
• Morbidity and mortality are particularly problematic for infants, toddlers, children,
and the elderly
• Certain drugs are acutely hazardous, possessing single-dose lethality for children
• Immediate surroundings and bystanders can be exposed to acutely toxic APIs
(e.g., antineoplastics) via excretion (including sweat) from those undergoing
treatmentWell documented as a major public health problem in the U.S. are the
parallel but related problems of drug diversion (promoting abuse and
addiction) and accidental poisonings (pharmaceuticals being a major
cause of poisonings among children) (see references cited in:
Daughton, 2010a; Daughton and Ruhoy, 2011). Even so, these twowide-
ly recognized problems are not sufﬁciently factored into the decision
process used in prescribing. Efforts to reduce unintended poisonings, es-
pecially in children, would be greatly assisted if medications that are
most frequently involved with accidental poisonings were ﬂagged so
that the appropriate precautions could be taken during the prescribing
decision process. These include prescribing an alternative (especially if
the targeted indication for the initial drug is off-label), prescribing quan-
tities least likely to lead to unused leftovers, prescribing dose forms or
formulations for adults that are less desirable or accessible to children,
and ensuring that the patient understands the hazards involvedwith im-
proper storage of unused medication as well as the imperative for pru-
dent disposal of unwanted or used medication.
3.2. Prescribers' unintended impacts on bystanders
With each prescription issued for a targeted condition, prescribers
should therefore keep in mind that they are essentially (albeit
unintentionally):
− indiscriminately prescribing vanishingly small amounts of random
medications to others beyond the patient (including those forwhom
the medication might be contraindicated — pregnant women or in-
fants, or those with pronounced sensitivities);
− facilitating others to ingest trace levels of one or multiple “stealth”
APIs without their knowledge or consent — perhaps on a chronic
basis;
− creating the potential for making prescription-only medications
freely available to those without a prescription — when leftovers
are diverted (with the potential for increased morbidity and mor-
tality via abuse and unintended poisonings);
− exposing others to signiﬁcant levels of highly hazardous substances
via excretion (such as family members of those prescribed antineo-
plastics) (Daughton, 2010a).3.3. Minimizing the bystander impacts of prescribing
Clearly, given the realities of drug pharmacokinetics, unintended
bystander exposures to even properly prescribed medications or their
constituent APIs cannot be eliminated. But they can be reduced — by
the prudent selection of API, dose, quantity, and duration of each pre-
scribed medication regimen. Optimizing these variables should be
attempted by using evidence-based off-label prescribing. Because of a
lack of complete information (especially pharmacokinetics), optimizing
each of these criteria is often a hypothetical exercise.We argue, however,
that by paying attention to these criteria— andmaking the patient aware
of the numerous stealth “side-effects” and “bystander effects” of medica-
tion use (beyond the known adverse drug reactions: ADRs) — a larger
purpose could be served.
The current paradigm could be changed — where prescribers and
patients alike resort tomedication before alternative treatments. A varie-
ty of forceswithin the systems of health care often lead to a consideration
of pharmaceuticals as the ﬁrst line of treatment. Useful to considerwould
be alternative methods to treat chronic conditions that require control
beyond acute and rapid corrections. Indeed, a more methodical, holistic
approach may ultimately prove more efﬁcacious, with fewer down-
stream effects. Acknowledging the many hidden side effects of medica-
tions may serve to catalyze an ongoing discussion and debate regarding
society's complex relationship with drugs and how to design an environ-
mentally sustainable system for their optimal use by the patient and
society at large.
Table 2
Multifaceted advantages of prudent prescribing— reducing adverse outcomes for patient
health, public safety, and the environment.
Adverse outcome
reduced
Resulting from Reductions achieved via
Release of APIs to
the environment
API excretion (urine and
feces); release to sewers
from bathing (APIs
excreted in sweat and
APIs concentrated in
topical formulations);
release in landﬁll leachate
from disposal of leftovers
to trash
Shorter regimens; lower doses
(may avoid drug–drug
interactions, which can lead to
non-adherence and
accumulation of leftovers)
Incidence of
adverse events
in patients
Caused by higher-than
needed doses or
longer-than needed
durations of treatment
Infrastructure
costs to society
Disposal programs for
leftover, unwanted drugs;
additional treatment
needed for wastewater
and drinking water
Cost to patients Drug waste: leftover,
unwanted, and unused
medications
Eliminating need for
self-adjustment of dose by
skipping doses, dose-form
modiﬁcation (e.g., “pill splitting”
or crushing), or measuring less
(liquid dose-form); reducing
physician change in treatment;
reducing incidence of
polypharmacy and
non-compliance
Diversion, abuse,
and unintended
poisonings
Unsecured storage or
imprudent disposal of
new and unwanted drugs
(and used delivery devices)
Informing patient of acute
toxicity hazards (especially
drugs lethal to children in a
single dose)
Deterioration of
physician–patient
communication
Non-individualized,
one-dose ﬁts all
prescribing
Involving patients in
determining their personal
optimal dose (shared
decision-making may improve
outcomes); low doses allow
patient to possibly also beneﬁt
from theplacebo responsewhile
avoiding ethical dilemmas that
would normally be imposed on
the physician (de Jong and Raz,
2011)
Unintended
exposure of
bystanders
API excretion via sweat
followed by inter-dermal
transfer (problematic for
antineoplastics and other
hazardous drugs)
(Daughton and Ruhoy,
2009)
Informing patients of risks
(both in writing and verbally)
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prescriber's decision process?
The primary factor that promotes the entry of most APIs into the en-
vironment is excretion via urine and fecal material. Bathing has been
identiﬁed as a secondary route of API release to sewers for those drugs
whose primary use is via topical application and for many systemic
APIs that are excreted via sweat (Daughton and Ruhoy, 2009). In con-
trast, disposal of leftovermedications to sewersmay be amajor contrib-
utor onlywhen theAPIwould otherwise undergo extensivemetabolism
that does not result in reversible metabolic conjugates (Daughton and
Ruhoy, 2009). Except for disposal, these routes of release to the environ-
ment have long been considered intractable to control via pollution
prevention measures because they were viewed as natural, albeit
unintended, consequences of medication use not amenable to alteration.
And medications are viewed — rightly or wrongly — as essential for pa-
tient health, lifestyle, and well-being. This mind set has long impeded
productive physician–patient conversations of non-pharmacologic, alter-
native interventions.
The multifaceted advantages of prudent prescribing are summa-
rized in Table 2 and discussed further in the sections that follow.
3.4. Factors amenable to control for minimizing prescribing to bystanders
The initial dose determines the quantity of API excreted, even for
those drugs that are extensively metabolized (resulting in the excre-
tion of little of the unchanged parent API or its reversible conjugates);
for topical drugs, the amount applied determines the amount re-
leased during bathing (excluding the portion systemically absorbed)
(Daughton and Ruhoy, 2009). A certain portion of this prescribing is
responsible for the unnecessary introduction of an excess quantity
of APIs to the environment; this portion undoubtedly varies among
APIs. This excess portion could be actively reduced by a number of
strategies directly under the control or inﬂuence of the prescriber.
The only pollution prevention measure implemented to date is the
control of drug disposal to sewers. This has been addressed mainly by
the use of consumer collections called take-backs (Glassmeyer et al.,
2009). But drug disposal is probably only a minor contributor to the
levels of most APIs in the environment. Disposal might play a signiﬁcant
role only for those APIs thatwould otherwise be extensivelymetabolized
and not yield reversible conjugates (Daughton and Ruhoy, 2009). Sur-
prisingly, although the administered dose is recognized as themajor var-
iable responsible for most API release, it is widely discounted as one that
is not amenable to control measures. In fact, environmental models that
are designed to predict the concentrations of APIs in the aquatic environ-
ment almost always assume on-label doses (or assumptions regarding
combined daily doses, such as the deﬁned daily dose — DDD).
These assumptions retard the development and implementation
of healthcare practices that could result in the most signiﬁcant reduc-
tions of API loadings in the environment. To correct these ongoing
assumptions, we examined the feasibility of controlling drug dose as
a primary means for potentially reducing the entry of APIs to the en-
vironment. The problems that derive from failure to consider adjust-
ment of doses to levels lower than the “standard” (on-label) dose are
illustrated in Fig. 1. These problems result from the failure to consider
patients, society at large, and the environment holistically — as an in-
tegral “patient” (Daughton and Ruhoy, 2011).
4. Off-label dosing as a key strategy in minimizing impacts on the
environment and other bystanders
Captured in Fig. 1 are the major problems that can result from re-
liance on the standard (on-label) dose of a medication. The middle
portions of the illustration pertain to concerns related to human
health and safety. The upper and lower portions of the illustration relate
respectively to impacts on the aquatic and terrestrial environments. The
assumption is made in the illustration that the drug is being prescribedfor an indicated (on-label) condition— as a “standard” dose has no for-
mal meaning for an off-label condition, especially one not sufﬁciently
supported by evidence.
The box in Fig. 1 labeled “ADRs” might be more accurately labeled
“Preventable ADRs.” Although ADRs for off-label indications can be
frequently identiﬁed during post-market surveys, as the size of the treat-
ed population increases well beyond those used in clinical trials — and
some of these ADRs eventually become well known (e.g., off-label use
of fenﬂuramine-phentermine leading to cardiac valve damage)— the in-
tent of the illustration is to show the potential beneﬁts of off-label dosing
(particularly doses lower than recommended) for indicated conditions.
Note, however, that for a drug prescribed for an evidence-based
off-label indication, the same principles involved with lower-dose
prescribing can still apply. Many studies maintain that the large major-
ity of ADRs derive from higher-than-necessary on-label dose rather
than other aspects of prescribing such as an API's inherent pharmaco-
dynamics, errors, or patient non-adherence (Cohen, 2001b; Lazarou
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certain individuals.
For any API, the dose–response regime comprises targeted thera-
peutic effects and off-target, side effects (which subjectively may or
may not be considered ADRs). The “optimal”dose (the best compromise
between the two) is often determined by the patient in experimenting
with self-dosing adjustments. The box labeled “patient self-adjusted
dose” refers to the practice commonly used by patientswhodesire to ei-
ther begin ormaintain therapy at a dose below theon-label dose (e.g., to
avoid ADRs) but the lower dose is not available from the manufacturer
(or compounding pharmacy) or the patient does notwant the physician
to know about their non-adherence; cost savings may be another moti-
vating factor. This practice involves pill splitting (or crushing) or other
forms of “dose-form modiﬁcation” (such as dividing the contents of
emptied capsules), measuring less of a liquid dose-form, or using a
less-frequent dosing schedule; for tablets amenable to splitting (using
a well-designed splitter), the patient can often reproducibly create frac-
tional doses ranging down to one-eighth. Although it is well-known
that dose-form modiﬁcation can pose problems for the patient (such
as insufﬁcient doses for conditions lacking symptoms that the patient
can readily recognize; or the release of excessive API from dose-forms
not intended for physical modiﬁcation, such as time-release formula-
tions), less appreciated is that dose-form modiﬁcation can also pose
hazards for bystanders. The physical alteration of medications holds
the potential for unrecognized spillage of residues released from strug-
gling to split or crush oddly shaped drugs or tablets designed to resist
tampering. The released debris can later be accidentally contacted or con-
sumed by children or pets (Daughton, 2010a); if the intent is to encour-
age patient experimentationwith low doses, the prescribermight avoid
oddly shaped drugs that make pill splitting difﬁcult or time-released
dose-forms or tablets designed to defeat tampering.
Supporting references for parts of Fig. 1 include: (i) uptake/
bioconcentration of APIs by aquatic organisms (Daughton and
Brooks, 2011; Meredith-Williams et al., 2012) and their impacts in
the aquatic environment (Corcoran et al., 2010; Santos et al., 2010),
(ii) occurrence and health ramiﬁcations of APIs in drinking water
(Daughton, 2010b; Jelić et al., 2012), (iii) hazards of unintended
human poisonings from mishandling of drugs (Daughton, 2010a),
and (iv) overview of the issues surrounding patient non-compliance
and various other patient/physician behaviors that lead to the accu-
mulation and eventual need for disposing of unwanted, leftover
drugs (Daughton, 2010a). Important to recognize is that the illustra-
tion focuses solely on the parent API with respect to environmental
impact. Analogous concerns pertain to potential metabolites or trans-
formation products, including: (i) labile, reversible metabolic conju-
gates, which can later undergo hydrolysis to return the parent API
(Daughton and Ruhoy, 2009), (ii) environmental degradation products,
many of which are the same as excretedmetabolites (e.g., see: Celiz et al.,
2009; Hernández et al., 2011), and (iii) transformation products, such as
disinfection by-products (e.g., N-nitrosodimethylamine — NDMA) creat-
ed during water chlorination (Pereira et al., 2011; Shen and Andrews,
2011).
The subject of drug dosing is widely misunderstood. As recently as
40 years ago, medicine was more an art than a science. Management
of a patientwas a culmination of the skills, experience, and observations
of a physician along with patient speciﬁcs such as a demographics and
family history. Largely as a result of the advent of statistically controlled
clinical trials, prescribing of medications often now uses the “one size
ﬁts all” approach — rigidly adhering to the “standard” dose that is cap-
tured in the medication “label” (and reiterated in references such as
the Physicians' Desk Reference, or PDR). Many erroneously assume
that the standard dose should not be adjusted — to ensure therapeutic
efﬁcacy. Prescribers sometimes fear that adjusting the dose could lead
to ethical or legal vulnerabilities (Rosoff and Coleman, 2011). This
fear, however, is not well founded— as the standards of care for dosing
of most commonly used classes of medicinal drugs are not established.Furthermore, the FDA does not prohibit off-label prescribing (one as-
pect of which is dose), as it does not regulate the practice of prescribing
itself (Meadows and Hollowell, 2008); controlled substances are an ex-
ception where federal regulations do govern prescribing (Rosoff and
Coleman, 2011). Note, however, that off-label prescribing may be
viewed differently in other countries (e.g., see: Emmerich et al., 2012).
In fact, prudent off-label use is considered integral to the contin-
ual evolution and advancement of the accepted standard of care
(Tomaszewski, 2006); prudent off-label use also plays a role in
repurposing (or repositioning) drugs for new uses. For those clini-
cians hesitant to prescribe lower doses because of liability concerns,
an alternative perspective is that universally prescribing the stan-
dard (on-label) dose invariably and necessarily means that one or
more sub-populations are being over-medicated. These groups
should instead be receiving lower doses because they display dispro-
portionately higher responses at lower doses than indicated by the
composite (average) dose–response curve from the general popula-
tion. This recommendation inherently assumes that a physician is
able to offer regular follow up, which may be in the form of a clinic
visit or laboratory testing for evaluating a patient's response to a lower
dose.
In this discussion, the assumption is made that all prescribing is
for bona-ﬁde indications—where the possibility of positive therapeu-
tic outcomes is documented by sufﬁcient evidence for the selected
API. These include the indications covered by the label as well as
those sufﬁciently supported for particular off-label uses. Prescribing
for on-label indications involves drugs containing APIs that are com-
monly reported as environmental contaminants (e.g., see Supplementa-
ry Table S1). For those drugs prescribed for off-label indications lacking
unambiguous evidence of efﬁcacy in the absence of undue risk, avoid-
ance of these uses would clearly result in a reduction in environmental
API loadings.5. The role of prudent, off-label prescribing
It is critical to distinguish prudent from imprudent prescribing.
Off-label (“unapproved”) prescribing includes bona-ﬁde reasons to
adjust parameters beyond those accommodated by the label, such as
therapeutic indication (condition), dose strength and daily quantity,
dose frequency (interval), duration (course), route of administration,
age, or gender. Generally, this includes those variables not covered in
the drug registration data (such as clinical trials), or those speciﬁcs
that are actively excluded by the label (e.g., a speciﬁc contraindicated
sub-population or drug–drug interaction).
Despite the restrictions implied by on-label use, off-label use (jus-
tiﬁed with sufﬁcient supporting evidence) is a common and widely
accepted prescribing practice (Radley et al., 2006), especially for chil-
dren and other sub-populations that have historically been excluded
from clinical trials. Only in the absence of supporting evidence (or
the failure to acknowledge negative evidence) is off-label use consid-
ered imprudent, improper, problematic, or disapproved. Off-label use
essentially serves as the major mechanism for continually updating
the more limited knowledge base that existed at the time of licensing.
This is tempered, however, by a possibly widespreadmisunderstanding
among prescribers as to what exactly constitutes off-label use and the
key role of supporting evidence (Chen et al., 2009). Growing numbers
of resources provide access to information regarding evidence-based,
off-label use (e.g., Baker, 2008; Chen et al., 2009; Largent et al., 2009;
Stafford, 2012; Walton et al., 2008). Even with supporting evidence,
however, the physician should document all off-label prescribing deci-
sions to minimize liability vulnerabilities (Edersheim and Stern, 2009;
Rosoff and Coleman, 2011).
Important to note is that the published literature on off-label prescrib-
ing focuses predominantly on off-label indications and sub-populations.
Comparatively little attention is devoted to off-label dose.
Table 3
Examples of drugs prescribed for off-label indications with minimal strong supporting
evidence and which have also been identiﬁed as contaminants in the environment.
Druga Evidence for occurrence of API as environmental contaminantb
Amitriptyline [#53]
c
Wastewaters (Bisceglia et al., 2010; Unceta et al., 2010;
Verlicchi et al., 2012); biosolids (Chari and Halden, 2012)
[also see Table S1]
Azithromycin [#7] Wastewater or sewage sludge (Miège et al., 2009; Radjenovic et
al., 2009; Verlicchi et al., 2012); rivers or drinkingwater (Reif et
al., 2012; Valcárcel et al., 2011); biosolids (Sabourin et al., 2012)
Celecoxib (#74) Wastewater (MacLeod and Wong, 2010)
Citalopram [#19] Wastewaters (Breitholtz et al., 2012;MacLeod andWong, 2010;
Metcalfe et al., 2010; Unceta et al., 2010); treated wastewaters
and surfacewaters (Gros et al., 2012); rivers and drinkingwater
(Valcárcel et al., 2011); aquatic organisms (Daughton and
Brooks, 2011); sorbed to settleable particulates (Lahti, 2012;
Lahti and Oikari, 2011)
Clonazepam [#28] Sewage sludge (Fick et al., 2011) [lack of targeted monitoring
in waters]
Diclofenac [#97] Wastewaters (Stülten et al., 2008); treated wastewaters (Gros
et al., 2012; Yu et al., 2012a); sewage sludge (Yu andWu, 2012);
ﬁsh (Lahti et al., 2012)
Gabapentin [#20] Surface water (Ferrer and Thurman, 2012; Kasprzyk-Hordern
et al., 2008); wastewater (Lai et al., 2011); surface water and
drinking water (Morasch et al., 2010)
Olanzapine (#195) Wastewaters and surface water (Bahr, 2009; Gracia-Lor
et al., 2011)
Quinine [n.a.] Acute toxicity hazard for children (Daughton, 2010a;
references cited therein)
Risperidone [#80] Fish (Fick et al., 2010); wastewaters (Bahr, 2009; Woldegiorgis
et al., 2007)
Trazodone [#37] Surface waters and wastewaters (Gros et al., 2012;
Himmelsbach et al., 2006; Martínez Bueno et al., 2012)
a Drug frequently prescribed for off-label indications and which has weak supporting
evidence (Eguale et al., 2012).
b Representative recent references documenting API occurrence in ambient waters,
treated sewage efﬂuent or sludge, sewage biosolids, or aquatic tissues.
c Number in square brackets indicates ranking of API among the top 200most-frequently
prescribed generic drugs in 2010 (Drug Topics, 2011); number in italicized parentheses in-
dicates ranking of API among the combined top 200 most-frequently prescribed generic
and branded drugs in 2011 (Bartholow, 2012). Lack of number indicates API is not among
the most-frequently prescribed; note that this ranking does not include APIs from sales of
OTC medications.
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(less can be more)
In 2010, The Archives of Internal Medicine began publishing a series
of articles (“Less Is More”) on improving healthcare outcomes by
avoiding the over-application of care, such as by imprudent prescrib-
ing (Grady and Redberg, 2010). Informal guidelines for less-is-more
prescribing were outlined in one article from this series that presented
two-dozen principles underlying what is becoming known as “conser-
vative prescribing” (Schiff et al., 2011). These elements focused on
more prudent, judicious prescribing, with an emphasis on restricting
the types and numbers of medications prescribed to an individual pa-
tient. Absent, however, were considerations surrounding dose — or
the attendant indirect effects regarding accidental or unintended expo-
sure to others and the environment.
Imprudent prescribing includes purposeful use for off-label indi-
cations, aswell as for on-label indications using parameters not covered
by the label (e.g., excessive doses), in the absence of sufﬁcient evidence
or despite evidence to the contrary. Less appreciated is that it can also in-
clude adhering strictly to on-label use but resulting in unintended,
unforeseen off-label use (such as particular mismatches resulting from
uncoordinated polypharmacy contributed by multiple physicians). In-
deed, one study involving measures striving to actively reduce or dis-
continue polypharmacy in elderly patients was shown to not result in
signiﬁcant risks, but rather to result in improved health for 84% of the
patients (Garﬁnkel and Mangin, 2010). Particularly noteworthy with
respect to geriatric medicine is the precaution needed in avoiding
or reducing the dosage/duration of certain medications. The Beers
Criteria — updated in 2012 (The American Geriatrics Society Beers
Criteria Update Expert Panel, 2012) —were developed for informing
the prescriber of medications that may pose unwarranted risks for
older patients (AGS, 2012). Adherence to the Beers Criteria would re-
sult in immediate reductions in the environmental loadings of these
age-inappropriate medications.
The magnitude of imprudent prescribing is reﬂected in any num-
ber of reports. One notable example is a report from the Ofﬁce of In-
spector General (Department of Health and Human Services) that
documented widespread, imprudent, off-label prescribing for atypical
antipsychotic drugs in nursing homes for the elderly (Levinson, 2011).
This study targeted Medicare claims involving unnecessary use — de-
ﬁned in part as inappropriate indication (or contraindication), or excess
dose or duration. In this case, patients were subjected to unnecessary
risks, and healthcare was burdened by additional costs; API loadings
to the environment were undoubtedly unnecessarily increased.
Of note is that off-label imprudent prescribing (i.e., unsupported
by evidence) is not necessarily actively or uniformly regulated— except
for certain controlled substances. Over the years, however, many argu-
ments have been advanced for its regulation, including the larger issues
of societal harm resulting from collateral adverse effects that lead to in-
creased healthcare spending (e.g., Rosoff and Coleman, 2011).
All attempts to reduce imprudent prescribing clearly hold sub-
stantial potential for beneﬁtting the patient and further protecting
public safety (with reduced diversion and poisonings). But the argu-
ments supporting the need to regulate imprudent, off-label prescrib-
ing could be augmented by emphasizing the increased probability
that APIs are invariably and unnecessarily discharged to the environ-
ment — adding to the environmental loadings already resulting from
prudent prescribing. Prohibition of imprudent prescribing could have
ameasurable and immediate impact on reducing the loadings of various
types of APIs introduced to the environment.
Obvious drugs to ﬁrst target for reduced prescribing are those fre-
quently prescribed for off-label indications that have weak supporting
evidence and which also have been identiﬁed as contaminants in the
environment. As an example, some of the drugs highlighted in one
off-label use study (Eguale et al., 2012) are summarized in Table 3.
The records from 113 primary care physicians were examined for a5-year period, entailing roughly a quartermillion prescriptions for near-
ly 51,000 patients. These prescriptions involved 684 drugs. The inci-
dence of prescription for off-label indications was 11%, and of these,
79% lacked supporting evidence considered to be strong. The 11 drugs
listed in Table 3 are those with the highest off-label use for indications
with the lowest incidence of strong supporting evidence — ranging
from zero to less than 50%. Of these 11 drugs, eight were among the top
100 generic drugs prescribed in the U.S. in 2010 (Drug Topics, 2011).
Other, widely accepted examples of imprudent prescribing in-
clude those highlighted in the Choosing Wisely Campaign, which
was organized by the American Board of Internal Medicine Founda-
tion in 2012 (http://choosingwisely.org/) in response to a proposal
(Rosenbaum and Lamas, 2012) regarding the imperative and respon-
sibility of physicians to factor cost — in the form of waste avoidance
(Brody, 2012) — into their decision making. This campaign compiled
lists of “Five Things Physicians and Patients Should Question” from each
of nine U.S. medical specialty societies. Each of the 45 items on these
nine lists represents a consensus, evidence-based recommendation.
While the current lists focus almost exclusively on screening tests and
procedures deemed imprudent under certain conditions (e.g., unneces-
sary diagnostic tests, “defensive medicine”), many of these tests lead to
subsequent follow-up treatments that entail medications, often for
long-termmaintenance— a practice that particularly sustains and per-
petuates environmental loadings of APIs.
Two examples highlighted by the Choosing Wisely Campaign spe-
ciﬁcally target imprudent prescribing of medication (over-treatment)
and include avoiding antibiotics for certain sinusitis conditions and
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tamine H-2 receptor antagonists for gastroesophageal reﬂux disease.
Indeed, both ranitidine (Castiglioni et al., 2006; Pedrouzo et al.,
2011; Yu et al., 2012b) and omeprazole (Pedrouzo and Borrull, 2008;
Rosal et al., 2010) have been reported in treated sewage efﬂuent. And
the imprudent use of antibiotics poses unique concerns from wide-
spread contamination of the environment, especially in niches where
residues accumulate and concentrate (such as soils and sediments).
Concerns continue to emerge with respect to the selective pressure
for antibiotic resistance (and for cell persistence) among bacteria of
clinical concern from exposure to low, ambient levels of antibiotic
APIs (Tello et al., 2012). Other examples of drugs frequently prescribed
imprudently are those that pose acute risks for the elderly (e.g., Gloth,
2010).
A ﬁnal example involves controlled substances (Schedules II, III, and
IV) that are subject to doctor shopping and frequent abuse. These repre-
sent a particular group of drugs that experience high rates of imprudent
prescribing with particularly strong adverse impacts on both patients
and bystanders; they are also commonly identiﬁed as environmental
contaminants (Bijlsma et al., 2012; Daughton, 2011). This prescribing
could be substantially reduced by prescribers with more diligent and
effective referral to prescription-drug monitoring programs (PDMPs)
to track possible abuse by patients. Expansion of PDMPs and improved
ease of access would greatly help (Daughton, 2010a; Perrone and
Nelson, 2012).
7. The role of dose in mitigating APIs in the environment
Accounting for the potential impact of APIs on the environment as
a new factor in guiding the drug selection process used in prescribing
was conceptualized and introduced in Sweden in 2005 (Wennmalm
and Gunnarsson, 2005); an assessment of this system (Swedish Envi-
ronmental Classiﬁcation and Information System for pharmaceuticals)
has been made (Ågerstrand and Rudén, 2010). Three factors were con-
sidered in this ﬁrst-ever environmental classiﬁcation system for rank-
ing an API's potential for adverse environmental impact: (i) resistance
to microbial degradation (persistence), (ii) potential to bioaccumulate,
and (iii) ability to elicit adverse effects on non-target organisms ([eco]
toxicity) — PBT. An overview on integrating PBT as a consideration in
the prescribing process is presented by Castensson et al. (2009).
Absent from the considerations of PBT were two primary but
straightforward factors never before considered for guiding the prac-
tice of prescribing. These are: (i) the potential for the API to enter the
environment to begin with (usually dictated by its pharmacokinetics,
which governs excretion, and by its rate of non-compliance, which
may reduce excretion but promote sewer disposal of leftovers), and
(ii) reducing the entry to the environment of an API through simple
dose reduction (when warranted by therapeutic evidence). The sec-
ond approach (dose reduction) is the focus of this discussion. The
complexities involved with the ﬁrst factor were originally presented
in Daughton and Ruhoy (2009); this ﬁrst factor is important because
regardless of how unfavorable PBT criteria might be, they are of little
consequence if the potential for the API to enter the environment is
low.
Many variables involving dose and its administration play roles
not just in dictating the excretion of APIs but also in adverse drug re-
actions (ADRs), patient non-compliance, generation of leftovers, and
in the disposal or diversion of leftovers and their consequences deriv-
ing from abuse and poisonings. The major variables are summarized
in Table 4. Notably, most of these factors are interrelated in a network
of complex feedback loops. A change to one factor will often impart
changes to others. One factor that does not always negatively impact
drug wastage but which is important with respect to patient health is
the unintended forcing of non-compliant behavior by prescribing
higher-than-needed doses of medications a patient cannot afford; in
some of these cases, low-dose prescribing can promote complianceby making the prescription more affordable (e.g., Tseng et al., 2004).
Increased compliance is also known to lead to reduced overall health
care costs (Roebuck et al., 2011).
This paper focuses primarily on just one of these factors (dosage
strength and frequency), as it plays a central role in directly impacting
many of the other variables; analogous evaluations could be conducted
for each of the other variables in Table 4,most of which also pose oppor-
tunities for reducing API excretion. The inter-connectivity of these fac-
tors is shown in the following exemplary general scenarios, which are
also captured in Fig. 1.
Examples of APIs that have already been identiﬁed in the environ-
ment (excluding samples inﬂuenced by discharges from drug manu-
facturers) and whose ambient levels could be lowered by reduced
doses are presented in Table 5 and Supplementary Table S1. The latter
table includes the literature references that document each API's
identiﬁcation in representative environmental monitoring studies. It
also includes an indication of whether each API has been among the
top 200 most-frequently prescribed generic or branded drugs in the
U.S.; note that this ranking does not include APIs from sales of OTC
medications.
7.1. Example scenarios for drug dose promoting bystander impacts
The following general scenarios are pertinent to Fig. 1. A dose that
proves excessive for a patient (which may include the on-label dose)
will initially lead to the excretion of APIs (and bioactivemetabolites and
reversible conjugates) in excess of what would have resulted from a
lower, optimal dose. A higher-than-needed dose might also lead to
ADRs sufﬁcient to force non-compliant behavior and eventual cessation
of therapy (with resultant accumulation of leftover medications); in
particular, “ﬁrst-dose” ADRs are problematic for some drugs, such as
anti-hypertensives (Cohen, 2001a), leading to abrupt non-compliance
and showing the importance of initiating certain treatments with low
doses. An unnecessarily high dose might also create ADRs that are mis-
taken for independent comorbidities that mislead into treatment with
an additional API (leading to polypharmacy); in particular, the initiation
of a drug therapy may induce anxiety, whose symptoms could be mis-
taken for comorbidities. An unnecessarily high dose of a maintenance
medication could also lead a patient to self-adjust to lower doses
(e.g., via pill splitting/crushing or less-frequent administration); while
this might eventually guide the patient to a proper dose, it will also lead
to the accumulation of unused medications.
Non-compliance may prompt the physician to switch therapy to
another API (even though many ADRs derive from dose rather than
the API itself). Nonetheless, compliance may then improve with fewer
side effects — but new ADRs are also possible (caused by the API or by
genotoxic impurities). Either way, a therapy switch leads to the accu-
mulation of leftovers from the failed medication, which represents
wasted cost for the patient and a failure to have achieved the therapeu-
tic goal. Finally, non-compliant behavior resulting from excessive dose
may breed distrust in conventional medicine and lead to experimen-
tation with unapproved, imprudent alternative treatments, some of
which might include unapproved drugs (such as those accessible via
certain Internet pharmacies).
7.2. Some caveats regarding dose
In the published literature, discussion of “low” dose is sometimes
confused by two different meanings. One involves the lowest on-label
dose. The other involves an off-label dose below the on-label range.
Other adjectives are often used in attempts to provide a subjective
sense of “low,” including: lower, very low, ultra-low, micro-dose, and
sub-therapeutic. This all adds to confusion when searching the pub-
lished literature for pertinent references.
Although the dose for many drugs can be reduced while retaining
therapeutic efﬁcacy, situations occur where dose reduction is not a
Table 4
Major variables involving dose and its administration that can be optimized to reduce
excretion as well as the incidence of ADRs and leftovers.
Variable involved Example Problem exacerbated
Administration of dose
Route Enteral, parenteral, topical Dictates route of release of
API to environment
(excretion and bathing);
APIs in topical preparations
are highly concentrated
and often over applied
Dosage strengtha Quantity (e.g., mass) of
API per dose
Key consideration in
optimizing efﬁcacy, ADRs,
and patient compliance
Dose form (includes
API and formulation
ingredients)
Capsules, tablets, lotions,
aerosols, delivery device,
and speciﬁc forms such as
sustained/extended
release, etc.
Inﬂuences adherence and
dictates dosage
Dose purity Racemate versus
enantiopure
Racemic APIs with higher
enantiomeric eudismic
ratios result in excretion
of unnecessary,
non-therapeutic enantio-
mers (distomers); one ad-
vantage to chiral switches
Dosage regimen
(dosing frequency
or interval)
Number of doses and
their timing throughout a
day; must accommodate
duration of action
Deﬁned daily dose (DDD)
is an average collective
measure; PRN can promote
leftovers; complex regi-
mens degrade patient
compliance
Duration (course of
treatment)
Long-term, continual
maintenance versus
shorter term
Excessive duration poses
over-treatment risks to pa-
tients and contributes to
non-compliance, especially
when treatment endpoints
are not obvious to patient;
long-term treatment can
require periodic dose
adjustments
Titration (rate of
escalation from
a lower dose)
“First-dose” phenomena
(e.g., blood-pressure
medications); doubling of
dose versus smaller steps
May lead to
non-compliance
Timing/schedule Chronobiology (diurnal
rhythms) can affect
efﬁcacy and excretion
(Ravi Sankar et al., 2010)
Incorrect timing may
increase excretion or
reduce effectiveness
(thereby necessitating
increased dose); circadian
rhythms often control the
biosynthesis of many
proteins that serve as drug
receptors
Regimen complexity Complex, non-uniform,
episodic dosing; asynchro-
nous dosing; combination
therapy; polypharmacy
Drug–drug interactions
(often made worse by
pleiotropic APIs); patient
confusion leads to
non-compliance/adherence
Pharmacokinetic
proﬁle
Determines extent of
excretion of parent API
and reversible conjugates
(e.g., glucuronides)
Within a therapeutic class,
some APIs are more
extensively excreted than
others; long-acting versus
short-acting can increase
compliance; conjugates
can later be hydrolyzed
back to the parent API
Organoleptic
properties
Taste and odor Can cause non-compliance,
especially in children and
super-tasters
Dispensing of medication that promotes the generation of leftover medications
Total amount prescribed
or quantity dispensed
(quantity limit)
Number of doses dispensed
(e.g., 30-day or 90-day
stat supply)
Therapy failure and changes
in treatment lead to leftover
medications; excessive
quantities increase potential
for leftovers; small-quantity
trial prescriptions can reduce
leftovers
Table 4 (continued)
Variable involved Example Problem exacerbated
Reﬁll schedule Number of reﬁlls allowed Patients sometimes feel
obligated to reﬁll — even
when medication is no
longer needed or desired
Automatic reﬁlls Reﬁlls on predetermined
schedule
Patients sometimes fail to
stop automatic reﬁlls even
when no longer needed;
mail-order reﬁlls may con-
tinue when patient dies
Patient-speciﬁc intrinsic and extrinsic attributes
Individual, personal
variation in
pharmacokinetics (PK)
or pharmacodynamics
(PD)
Genetic polymorphisms
(e.g., leading to slow
versus fast metabolism;
responders versus
non-responders)
Can lead to either
increased, reduced, or
otherwise unnecessary
excretion of bioactive
chemicals depending on
the API; the advent of
companion diagnostics for
small-molecule APIs will
greatly assist in more
targeted treatments
Compliance/adherenceb Failure to consume full
regimens; causes span a
wide spectrum — from
purposeful decisions to
subconscious behavior
Patient adherence/
compliance is an extremely
complex topic and is one of
the major factors leading to
leftover drugs; affected by
the design of the dosing
regimen and its
complexity, frequency and
severity of ADRs, and
innumerable other factors
(Daughton, 2010a)
Polypharmacy Excessive number of
distinct APIs used for
multiple conditions; can
result from multiple
monotherapy or
combination therapy;
may result from failure of
multiple prescribers to
coordinate
Excessive “pill burden”
promotes non-compliance
and leftovers; prescriber/
patient medication reviews
can reduce incidence of
polypharmacy; for APIs
sharing the common MOA
(and therefore have additive
effects), doses can often be
reduced accordingly
Diet/nutrition, fasting
status
Including alcohol
(Fagerberg et al., 2012)
and tobacco consumption
Drug-nutrient interactions
affect PK/PD, impairing
effectiveness or causing
ADRs — all leading to
non-compliance (Laviano
and Fanelli, 2012)
Health status Renal, hepatic, and
cardiopulmonary
dysfunction
Impaired function can
profoundly affect excretion
Gender, age, race,
ethnicity, body
fat/weight
Major variables affecting
the PK/PD of dose
Children (Ekins-Daukes et al.,
2003) and the elderly (Shah,
2004) in particular may be
unusual in processing APIs
and require lower doses
Most of these factors have been discussed in Daughton (2010a) and Daughton and Ruhoy
(2011) and in the references cited therein.
a Dosage (API quantity and frequency of administration) is the focus of this paper.
b Patient non-compliance is sometimes used in a more general sense to also include
non-adherence, as they both can lead to the generation of unused, leftover doses, re-
gardless of the motivating behavior.
Dispensing of medication that promotes the generation of leftover medications
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uations where life is threatened or for conditions where the incidence
of the endpoint is so infrequent (e.g., seizures) that experimenting
with upward or downward titration is not possible. Low dose may
be imprudent where an immediate therapeutic response is required
(acute pain, acute asthma, severe infections by indicated pathogens).
Examples include the off-label low-dose administration of antibiotics
for infections, especially in children. This is the primary off-label use
of drugs in children, a population needing special considerations re-
garding dosages (Ekins-Daukes et al., 2003). Note, however, that the
Table 5
Examples of common APIs having evidence for lower, effective (off-label) doses and
with evidence of also occurring in the environment.a
Acebutolol Ezetimibe Omeprazole
Amitriptyline Famotidine Ondansetron
Amlodipine Felodipine Penbutolol
Atenolol Fexofenadine Pravastatin
Atorvastatin Fluoxetine Propranolol
Bisoprolol Flurazepam Ramipril
Bupropion Furosemide Ranitidine
Captopril Hydrochlorothiazide Sertraline
Celecoxib Ibuprofen Sildenafil
Cerivastatinb Imipramine Simvastatin
Chlorthalidone Lisinopril Spironolactone
Cimetidine Losartan Sumatriptan
Colchicine Lovastatin Torsemide
Diclofenac Metoprolol Trazodone
Doxepin Misoprostol Triamterene
Enalapril Nefazodoneb Venlafaxine
Estrogens (conjugated) Nizatidine Verapamil
Ethacrynic acid Nortriptyline Zolpidem
aGeneric names arranged in alphabetical order for 53 commonly prescribed APIs
(and one discontinued). Many of these APIs have been identiﬁed in environmental
monitoring surveys of treated and untreated sewage and of ambient waters or sediments
(see Supplementary Table S1). Shaded cells indicate that API is not commonly reported in
environmental monitoring surveys or has never been targeted for monitoring.
bCerivastatin was withdrawn from the market in 2001; nefazodone brand-name sales
were partly discontinued beginning in 2003.
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may have bona-ﬁde uses for other indications; one example is the use of
low-dose tetracyclines formodulating over-expression of inﬂammatory
matrix metalloproteinases (e.g., use of 20-mg doses of doxycycline for
reducing collagenase activity in gingival disease).
Certain APIs have relatively ﬂat dose–response curves. While this
might seem to justify lower doses, the duration of action must also be
considered. One example is the angiotensin-converting enzyme (ACE)
inhibitors. If a lower but just as effective dose is selected, the shorter du-
ration of action can lead to adverse ﬂuctuations in blood pressure for
hypertensive patients (Taddei et al., 2011).
In certain critical situations, higher than normal “loading” doses
may be prudent at the initiation of therapy to rapidly increase plasma
levels. In some situations, doses higher than the on-label dose may be
more efﬁcacious. One example is statin maintenance treatment for
coronary artery disease (Mark et al., 2008; Rosen et al., 2010); another
example is with antiepileptic medications prescribed for seizure control.
Even when standard doses (or even supraphysiological doses) are
called for at the outset of treatment, subsequent downward titration
may be prudent for long-term treatment. In fact, success with down-
ward titration might eventually reveal that a drug is no longer needed
(Therapeutics Initiative, 1995).
For substantial numbers of medications, sufﬁcient evidence can
usually be obtained to justify lower doses — at least for the initiationof therapy. Obvious general indications include any chronic or mild
condition not requiring an immediate intervention. One example —
which attracts substantial over-prescribing— is mild-to-moderate de-
pression, where prudent prescribing may involve initiation at low doses
and followed, if needed, by titration in either direction (de Jong and Raz,
2011). Another example is the neuroprotective use of statins (such as
simvastatin) in reducing the risk of stroke (García-Bonilla et al., 2012);
caution is required in striving for the necessary, effective higher doses,
as such aggressive use can overcorrect targeted LDL (low-density lipo-
protein) levels —where levels too low can increase other risk factors.
Some medications have subjective dosing instructions. These re-
quire more attention by the prescriber in describing prudent use to
the patient. A general example comprises the high-content topicals,
where proper, controlled application requires diligence and attention;
over-application by hand (when an integral delivery device is lacking)
is common and often unavoidable by the patient. High-content topicals
using those APIs having limited enteral or parenteral approved uses
may be responsible for a disproportionate share of release to the envi-
ronment via bathing and can result in substantial inter-dermal transfer
to others and to the immediate, made environment — especially sur-
faces (Daughton and Ruhoy, 2009).
Methods are sometimes available for predicting proper doses
based on the patient's personal pharmacokinetics. One example of
personalized dosing (for risperidone) bases the dose calculation on
two time points for plasma concentrations (Uchida et al., 2012).
In some situations where the dose needs to be increased, alterna-
tive approaches might achieve better outcomes. For example, drugs
with the same mode of action but different mechanisms of action
can sometimes be co-administered — each at a low dose but with ad-
ditive effects (Dimmitt and Stampfer, 2009). Clinical studies involving
ﬁve classes of blood-pressure medications show that combining low
doses (one-half the standard dose) of drugs from two or three different
classes yielded onlymoderately reduced efﬁcacy but disproportionately
lower incidence or severity of ADRs compared with a single drug at a
conventional dose (Law et al., 2003). Alternatively, low dose (or some-
times elimination of dose) combined with alterations to lifestyle and
other behaviors (e.g., adoption of healthful nutrition and exercise, or
avoidance of risky behaviors such as smoking or alcohol consumption)
is often an effective and more sustainable treatment approach — albeit
usually more challenging for the patient.
Finally, some medications are available in approved (on-label) dos-
age ranges that span 20-fold and more, such as for anti-hypertensives
(Cohen, 2001a). For these, selecting the lowest on-label dose is clearly
one strategy requiring no justiﬁcation for the majority of indications.
For those medications having broad, approved dose ranges, success
with the lowest on-label dose could indicate the potential for excur-
sions to yet lower, off-label doses. For drugs with notoriously poor pa-
tient compliance because of ADRs (e.g., anti-hypertensives) or drugs
that are costly for the patient, such a strategy might be welcomed by
the patient.
The prudence of low-dose off-label prescribing for non-severe condi-
tions is partly substantiated by the incidence of over-the-counter (OTC)
switches. Drugs thatwere once available only by prescription and at com-
paratively high doses that spanned narrow ranges (purportedly justiﬁed
by manufacturer claims that lower doses would be ineffective) later
become available OTC but at lower doses (Cohen, 2003). Also of possible
relevance is that comparedwith theU.S., the approveddose range is often
lower in the EU and invariably lower in Japan (Malinowski et al., 2008).
8. The role of lower-dose prescribing
Many physicians are not aware of the advantages sometimes afforded
by lower-dose prescribing. By highlighting that unnecessary API contam-
ination of the environment occurs as a consequence of non-optimal
prescribing, the role of lower-dose prescribing might gain more traction.
Lower-dose prescribing could be advantageous for many, including:
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proved therapeutic efﬁcacy), “bystanders” (reducingmorbidity andmor-
tality from accidental poisonings in non-users, and inadvertent exposure
to hazardous drugs excreted via sweat from chemotherapy patients),
municipal infrastructure (reduced costs associatedwith the need to dis-
pose of excess leftovers), physicians (improved patient relations and
communication, and trust and respect from the patient), and the envi-
ronment (reduced API burdens).
Campaigns for more attention to dose reduction began to achieve
momentum in the 1980s–1990s (e.g., Therapeutics Initiative, 1995).
Since then, widespread evidence has evolved to show that the therapeu-
tic effectiveness of off-label, low doses often matches — and sometimes
exceeds — that of on-label drug doses. This evidence has grown sufﬁ-
ciently that some have called for revisiting the dosing guidelines for
manymedications and creating a ready and authoritative source that pre-
scribers can access for emerging evidence regarding effective low-dose
therapies not covered in traditional resources such as the PDR (Cohen,
2001a; Dimmitt, 2011). More direct approaches would be to encourage
clinical trials to evaluate the lower end of the dose–response curve and
to compile data mined from the published literature into a centralized
database.
In the ongoing compilation of pharmacovigilance and post-market
(Phase 4) efﬁcacy data, recommended doses for many drugs are often
readjusted — more often downward than upward. For example, an
evaluation of the 71% (354) of the new molecular entities approved
by the FDA from 1980 to 1999 revealed that 21% later experienced
on-label dose changes. Among the 73 that were changed, 79% were
adjusted downward; the dominate category (27%) comprised neuro-
pharmacologic drugs (Cross et al., 2001). Similarly, a study of DDD for
the period 1982–2000, reported 115 instances of adjustments, with
61% downward compared with 39% upward (Heerdink et al., 2002).
One obvious driver for the need to initiate treatment at lower doses
involves drugs having very narrow therapeutic ranges — where thera-
peutic effects and toxicity are closely positioned on the dose–response
curve. Another driver to remain at the lower end of the dosage range
is when the dose–response curve ﬂattens — where efﬁcacy gains fall
precipitously and ADRs rise with incrementally increased dose. Com-
plicating this, however, is that medications are often manufactured
in a limited (and sometimes restrictive) range of doses. The need for a
lower, non-standard dosemay necessitate other strategies such as phar-
macy compounding, dose-formmodiﬁcation, or dose skipping; each has
disadvantages. Even so, low-dosages pose many potential advantages.
Two important potential beneﬁts frequently overlooked are: (i) the
empowering of patients by encouraging self-titration to the lowest effec-
tive doses (this, in turn, can promote better compliance and ultimately
achieve therapeutic goals more reliably), and (ii) permitting the pre-
scriber to ethically administer doses sufﬁciently low that a portion of
the drug's action may derive from the placebo response (McCormack
et al., 2011).
8.1. Barriers to low-dose prescribing
The traditional linear, monotonic dose–response curve forces the
conviction that lower doses are increasingly and proportionately
less effective. With growing interest in the toxicological aspects of
the lower end of the dose–response curve, such as for studies of ex-
posure to trace levels of environmental or occupational toxicants
(e.g., carcinogens), low-dose action is emerging as a complex and
possibly signiﬁcant toxicological process. This is compounded when con-
sidered within the larger context of mixture toxicity and the fact that
seemingly paradoxical non-monotonic (andmulti-phasic) dose–response
at low levels is attracting more scrutiny and debate (e.g., Daughton,
2010b; Rhomberg and Goodman, 2012; Vandenberg et al., 2012). APIs
are no different than other xenobiotic chemicals in the sense that the
potential for biological activity at diminishingly low exposure levels is
a largely unexplored area of toxicological science.8.2. Examples of drugs with evidence supporting therapeutic efﬁcacy for
low-dose, lower-dose, fractional dose, or sub-therapeutic dose
Much has been published on the efﬁcacy and advantages of low-dose
treatment— including the fact that “less can bemore.”Many speciﬁc ex-
amples of commonly used drugs with evidence supporting lower doses
are presented in a number of general overviews: Cohen (2000; see
Table 2, therein), Cohen (2001a; see Table 1, therein), Cohen (2001b),
Dimmitt and Stampfer (2009), and McCormack et al. (2011; see Table
1, therein). From these published examples, 53 APIs have been com-
piled in Table 5. Effective doses are commonly one-half to one-quarter
(and sometimes lower) of the on-label low dose.
Table 5 also indicates whether environmental monitoring data have
been published — showing whether the API is reported to occur as a
contaminant in the environment. For these 53 APIs amenable to lower
dosing, environmental monitoring data for 38 (72%) indicate their
occurrence as environmental contaminants. This shows that lower
doses of these particular 38 APIs could help reduce their levels in the en-
vironment. The supporting references are available in Supplementary
Table S1. In Table S1, it is apparent that of these 38 APIs only six have
not originated from the combined top 200 generic and branded drugs
prescribed in the U.S. (2010–2011).
The shaded cells in Tables 5 and S1 indicate that minimal evidence
exists for 15 of these APIs being reported in environmental monitor-
ing surveys. The lack of environmental data can result from either the
absence of data (never targeted in monitoring) or from data of ab-
sence (targeted by monitoring but never detected). The latter could
occur, for example, if an API were extensively metabolized, with little
parent API or conjugate being excreted [celecoxib is one example
(Paulson et al., 2000)], or if the analytical methodology was insufﬁcient
(e.g., levels too low for detection; or conjugates, if present, are not pur-
posefully hydrolyzed prior to analysis). In contrast, certain APIs with
little evidence for environmental occurrence may simply represent an
absence of data; one example (Table 5) is ezetimibe,which is extensive-
ly excreted as a reversible conjugate (Patrick et al., 2002).
Also note that the absence of an API in the environment does not
rule out the potential for environmental consequences because ex-
creted metabolites or transformation products (such as disinfection
by-products) may possess biological activity of their own. For example,
APIs (or their metabolites) that contain the dimethylamine (DMA)moie-
ty can serve as precursors to N-nitrosodimethylamine (NDMA), a carcin-
ogen that can be formed during water disinfection with chlorine. For
example, of the common APIs compiled in Table 5, ﬁve with DMAmoie-
ties (ranitidine, nizatidine, amitriptyline, sumatriptan, and venlafaxine)
have been shown to form NDMA (Shen and Andrews, 2011).
Certain drug classes have attracted abundant attention with re-
gard to the potential therapeutic importance of lower dose. A major
example comprises the selective serotonin reuptake inhibitor (SSRI)
antidepressants. A survey of the literature on the use of SSRIs by general
practitioners and psychiatrists for the treatment of mild-to-moderate
depression points to a controversy regarding dose (de Jong and Raz,
2011). SSRIs are frequently prescribed at initial or maintenance doses
below the lowest on-label dose — often at purported sub-therapeutic
doses. Evidence often shows little added therapeutic effect from SSRIs
compared with a placebo in mild-to-moderate depression, while both
treatments offer signiﬁcant beneﬁt compared with no treatment. In
this situation, low-dose treatment might be serving as an ethical imple-
mentation of surreptitious placebo treatment — so-called “convenient
placebos” (de Jong and Raz, 2011)—while at the same time also serving
to avoid ADRs from the use of conventional doses.
9. The future
The argument can be made that adjustment of dose to the lowest
that meets the individual patient's requirements for optimal balance
of efﬁcacy and ADRs is an obligation fundamental to the practice of
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sub-optimal treatment of the patient and the environment is un-
avoidable — and harm to both is more difﬁcult to avoid. To accom-
plish this, greatly improved promulgation to clinicians of data from
emerging low-dose efﬁcacy studies will be required (Cohen, 2001b).
Perhaps the most pressing challenge faced by truly informed,
evidence-based medicine is gaining access to currently inaccessible
clinical trial data— especially data from individual patients. The extent,
quality, and usefulness of the unpublished data generated from public
and private clinical trials are unknown but potentially very signiﬁcant;
progress has been made by journals and by the U.S. FDA in requiring
more timely publication of clinical trial data (e.g., via ClinicalTrials.gov).
Those striving to distill and synthesize what might be revealed by these
data have only recently had success in gaining access to comprehensive
and often voluminous data ﬁles (e.g., see commentaries by: Grens,
2012; Lehman and Loder, 2012). These data could have signiﬁcant inﬂu-
ence onwhatwas previously knownnot just about efﬁcacy but also per-
haps dose. As one example, consider a recently published re-analysis of
previously published 42meta-analyses that had involved efﬁcacy stud-
ies of nine drugs from six drug classes. After incorporating previously
unpublished trial data retained by the FDA, efﬁcacy was revealed to be
lower for 46% of the cases and higher for 46% (remaining unchanged
for only 7%) (Hart et al., 2012).
Access to unpublished data poses enormous challenges. And even
if successful, an efﬁcient mechanism would then be needed to pro-
mulgate the ﬁndings to practicing clinicians. One possible approach
for improving prescribers' selection of optimal dose would be the use
of academic detailing (Benjamin et al., 2011; Stowell et al., 2009). The
initial focus could begin with those most frequently prescribed drugs
(or those prescribed representing the largest mass of API) and also
having sufﬁcient evidence supporting lower doses. This group would
be further selected on those drugs whose APIs are known to widely
occur in the environment (e.g., see: Verlicchi et al., 2012), together
with those drugs having insufﬁcient evidence supporting prescribed
indications. A cursory examination of the classes of APIs commonly iden-
tiﬁed in the environment shows them to closely— but not surprisingly—
overlap with the ones that tend to be collected as leftover waste in con-
sumer take-backs. In one study of take-backs, for example, two-thirds of
the consumer-returnedmedications comprised CNS agents (23%), cardio-
vascular agents (15%), psychotherapeutic agents (15%), anti-infectives
(7%), and gastrointestinal agents (6%) (Kaye et al., 2010).
In addition to reducing dose directly, other options could eventu-
ally become routinely available to the prescriber for indirectly facili-
tating reduced dose. These would capitalize on various aspects of
pharmacokinetics — especially improving absorption of the API or
retarding metabolism or excretion (thereby increasing elimination
half-life) — by way of designed interactions with co-administered
drugs or dietary measures that impact metabolism. One of possibly
many examples is shown in a recent clinical trial of an existingmacrolide
drug (sirolimus — or rapamycin) under evaluation for a new purpose
(cancer treatment). Doses of rapamycin could be reduced to 28% and
lower when co-administered with another active agent known to inhibit
metabolism (Cohen et al., 2012) — in this case an antifungal drug
(ketoconazole) or grapefruit juice (which contains CYP-inhibitory
furanocoumarins and polyphenols). Of course, many other approaches
exist for effectively lowering dose, but most are not under the control
of the prescriber. Examples include drugs designed or formulated to en-
hance absorption, or delivery devices designed for improved targeting
or more efﬁcient delivery.
Not to be overlooked in this discussion of dose reduction for re-
ducing environmental API loadings is a parallel approach that would
focus on APIs having little potential for entry to the environment intact
or as bioactivemetabolites. Some APIs, for example, are extensivelyme-
tabolized and also do not undergo excretion as reversible conjugates
that can later undergo hydrolysis (deconjugation). One example of an
API with such pharmacokinetics — and which has not been routinelydetected in environmental monitoring (Table 5) — is celecoxib
(Paulson et al., 2000). APIs possessing excretion proﬁles that are inher-
ently protective of the environment could be noted as having little po-
tential to impact the environment as a result of intended use.
In the ﬁnal analysis, the prescriber's concept of the “patient” actually
extends to our immediatemade environment, the natural environment,
and other “bystanders.” Any prescribed treatment can have unantici-
pated, collateral impacts that are far reaching and which may incur
impacts and costs beyond those commonly considered. Attention to
reducing these collateral impacts from non-optimized prescribing —
especially via the use of lower, optimized dosing— could have recipro-
cal beneﬁts for therapeutic outcomes and reduced costs for patients and
society. Monetary costs in the form of waste avoidance is a consider-
ation gaining traction in the medical community (Brody, 2010) and
one for which optimal, reduced dose could certainly play a key role.
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